Phigenix is a renowned brand that specializes in providing advanced diagnostics and therapeutics for cancer patients. Founded in 2007 by Dr. Carlton D.

Donald, a highly experienced molecular biologist and cancer research scientist, Phigenix aims to change the landscape of cancer treatment. Dr. Donald brings over 25 years of expertise in the field and has made significant contributions to the understanding of cancer initiation, progression, and tumor immunity.

The brand is equipped with a team of dedicated professionals, including Mrs. Wennifer H. Donald, Director & Vice-president/COO, who has extensive experience in business management.

Dr. J. Page Brown, Director & Head of Research and Development, brings his pharmaceutical knowledge and project management skills to drive product development.

Dr. Charles A. West, Director and Head of Business Development, specializes in optimizing economic opportunities and has a successful entrepreneurial track record.

Mr. Scott Cha-Choe, Director, utilizes his strategic planning and business development experience to contribute to the brand's growth. Dr.

Richard A. Roy, Lead Medical Advisor, provides valuable medical expertise to ensure the highest quality of care for patients. Phigenix is committed to offering innovative solutions for prostate and breast cancer, leveraging cutting-edge research and advancements in the field.

With a dynamic team and a passion for cancer research, Phigenix is at the forefront of revolutionizing cancer treatment and improving patient outcomes